Vision Statement

To advance the science of neurotherapeutics and to improve and accelerate the development of new treatments.
### ASENT Corporate Partners
**List as of February 13, 2014**

<table>
<thead>
<tr>
<th>Level</th>
<th>Amount</th>
<th>Companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platinum</td>
<td>$25,000 +</td>
<td>Eisai, Inc., Janssen Scientific Affairs, Inc.</td>
</tr>
<tr>
<td>Silver</td>
<td>$5,000 - $9,999</td>
<td>INC Research, LLC, PPD, Inc., SK Biopharmaceuticals/SK Life Science, UCB, Inc., Upsher-Smith Laboratories, Inc.</td>
</tr>
<tr>
<td>Supporter</td>
<td>$1,000 - $2,499</td>
<td>Chase Pharmaceuticals Corporation, Cytokinetics, Inc., NeuroPace, Inc., Zalicus, Inc.</td>
</tr>
</tbody>
</table>
Table of Contents

Meeting Room Layout ....................................................... 2 - 3
Program Schedule .............................................................. 4
Information Exchange and Poster Presentations ....................... 6
Annual Business Meeting .................................................... 10
Meeting Evaluation/How Do I Obtain CME Credits? ................... 14
Continuing Medical Education Information ............................ 15
16th Annual Meeting Program Committee ............................. 19
ASENT Board of Directors .................................................. 20
Schedule-At-A-Glance.......................................................... Back Cover
Main Level
Program Schedule

**WEDNESDAY, FEBRUARY 19, 2014**

<table>
<thead>
<tr>
<th>6:00 p.m. – 8:00 p.m.</th>
<th>Welcome Reception</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grand Ballroom C,</td>
<td></td>
</tr>
<tr>
<td>Main Level</td>
<td></td>
</tr>
</tbody>
</table>

**THURSDAY, FEBRUARY 20, 2014**

<table>
<thead>
<tr>
<th>8:00 a.m. – 12:00 p.m.</th>
<th>Commonalities in the Development of Clinical Trial Measures in Neurology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grand Ballroom A/B,</td>
<td>Main Level</td>
</tr>
</tbody>
</table>

Program

Co-Chairs: Jesse Cedarbaum, MD, Consultant; Robin Elliott, MA, Parkinson’s Disease Foundation; Karl Kieburtz, MD, University of Rochester; Marc Walton, MD, PhD, FDA

8:00 a.m. – 8:05 a.m. | Presidential Welcome  
Michael Rogawski, MD, PhD, University of California, Davis

8:05 a.m. – 8:25 a.m. | Introduction  
Marc Walton, MD, PhD, FDA

8:25 a.m. – 8:45 a.m. | CAMD and C-Path Introduction  
Diane Stephenson, PhD, Critical Path Institute

8:45 a.m. – 9:00 a.m. | C-Path MS Outcomes Assessment Consortium  
Richard Rudick, MD, Cleveland Clinic

9:00 a.m. – 9:15 a.m. | Alzheimer’s Association Alzheimer’s Disease Initiatives  
Maria Carrillo, PhD, Alzheimer’s Association

9:15 a.m. – 9:30 a.m. | Parkinson's Disease: Updating the UPDRS  
Glenn Stebbins, PhD, Rush University Medical Center

9:30 a.m. – 9:45 a.m. | Motor Neuron Diseases  
Douglas Kerr, MD, PhD, Biogen Idec

9:45 a.m. – 10:00 a.m. | Panel Discussion

10:00 a.m. – 10:20 a.m. | Break

10:20 a.m. – 10:40 a.m. | NIMH Research Domain Criteria Initiative (RDoC): A Framework for Psychopathology Research  
Jill Heemskerk, PhD, NIMH/NIH

10:40 a.m. – 11:00 a.m. | NINDS-CDE  
Wendy Galpern, MD, NINDS/NIH

11:00 a.m. – 11:20 a.m. | Outcome Measures for Neurological Trials  
Petra Kaufmann, MD, MSc, NINDS/NIH

11:20 a.m. – 11:40 a.m. | Including the Patient Voice in the Development of Rating Scales  
David Cella, PhD, Northwestern University

11:40 a.m. – 12:00 p.m. | Wrap-Up Discussion  
Laurie Burke, RPh, MPH, LORA Group, LLC  
Maria Isaac, MD, PhD, European Medicines Agency  
Billy Dunn, MD, FDA
### THURSDAY, FEBRUARY 20, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 p.m. – 1:15 p.m.</td>
<td>Clinical Trial Measures Working Groups Luncheon</td>
</tr>
<tr>
<td><strong>White Oak, Lower Level</strong></td>
<td><strong>Incorporating the Patient Voice in the Presence of Cognitive Limitation</strong>&lt;br&gt;<strong>Assessing ADLs Across Indications</strong>&lt;br&gt;<strong>Developing New Instruments: Starting from Scratch vs. Composites of Existing Items</strong>&lt;br&gt;<strong>Assessment of Motor Function Across Neurological Diseases</strong>&lt;br&gt;<strong>Assessing Cognition Across Neurological Diseases</strong>&lt;br&gt;<strong>Assessment of Sensory Function Across Diseases</strong>&lt;br&gt;<strong>Assessing Mood and Anxiety in Neurological Disorders</strong>&lt;br&gt;<strong>Issues in AD</strong>&lt;br&gt;<strong>Issues in PD</strong>&lt;br&gt;<strong>Issues in MS</strong>&lt;br&gt;<strong>Issues in ALS</strong></td>
</tr>
<tr>
<td>1:15 p.m. – 1:45 p.m.</td>
<td>Reports and Wrap-Up</td>
</tr>
<tr>
<td><strong>White Oak, Lower Level</strong></td>
<td><strong>2:00 p.m. – 5:00 p.m. Science Non-Fiction in Neurotherapeutics</strong></td>
</tr>
<tr>
<td><strong>Grand Ballroom A/B, Main Level</strong></td>
<td><strong>Welcome and Introduction</strong>&lt;br&gt;Martha Morrell, MD, NeuroPace, Inc.</td>
</tr>
<tr>
<td>2:00 p.m. – 2:05 p.m.</td>
<td><strong>Applications of Nanotechnology for Treatment of Diseases of the Nervous System</strong>&lt;br&gt;Gabriel Silva, PhD, UCSD Jacobs Retina Center</td>
</tr>
<tr>
<td>2:05 p.m. – 2:35 p.m.</td>
<td><strong>Optogenetics: Tools for Analyzing and Repairing the Nervous System</strong>&lt;br&gt;Anthony Zoros, PhD, MIT Media Lab</td>
</tr>
<tr>
<td>2:35 p.m. – 3:05 p.m.</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>3:05 p.m. – 3:20 p.m.</td>
<td><strong>Reliable Neural Interfaces for Neurotherapeutics</strong>&lt;br&gt;Jack Judy, MD, PhD, Nanoscience Institute for Medical and Engineering Technology, University of Florida</td>
</tr>
<tr>
<td>3:20 p.m. – 3:50 p.m.</td>
<td><strong>2:00 p.m. – 2:05 p.m.</strong></td>
</tr>
</tbody>
</table>

**Program**

Chair: Martha Morrell, MD, NeuroPace, Inc.
Since 1999, ASENT has sponsored a poster session of new and previously unpublished data from physicians, researchers and this industry in the field of neurotherapeutics. All posters are peer reviewed, and accepted posters will also be published in ASENT’s journal, *Neurotherapeutics®*.

In addition, previously published data, preliminary data and/or previously reviewed posters are also welcome. These posters will not be published in the journal.

The poster session is an opportune time for academicians to showcase potential therapeutic opportunities to the industry and for the industry to provide review data on the progress of their approved or unapproved therapies. Join us in the poster session, and meet the presenters and discuss their projects.

(See the Abstract Descriptions handout available at the Information Exchange.)
THURSDAY, FEBRUARY 20, 2014

3:50 p.m. – 4:20 p.m.  Brain Machine Interfaces for Language Prostheses  
Brian Pasley, PhD, Helen Wills Neuroscience Institute, University of California, Berkeley

4:20 p.m. – 4:30 p.m.  CDRH Office of Science and Engineering Laboratories  
Victor Krauthamer, PhD, FDA, CDRH and OSEL

4:30 p.m. – 5:00 p.m.  Panel Discussion

3:30 p.m. – 5:00 p.m. Animal Research and Brain Diseases  
Linden Oak, Lower Level

Hosted by the American Brain Coalition and the Society for Neuroscience, with support from the Esther A. & Joseph Klingenstein Fund, Inc.

Humane and well-regulated animal research is an essential component in the development of treatments for brain diseases. Hear perspectives from a scientist, a clinician, and a patient, and engage in a thoughtful conversation on the importance of animal research. The panel will be moderated by Mark Rasenick, distinguished University of Chicago professor and American Brain Coalition Advocacy Chair, who studies the neuroscience of depression and antidepressants.

5:00 p.m. – 6:30 p.m. Information Exchange and Poster Presentation Reception

6:30 p.m. – 8:30 p.m. Dinner Session: Conflict of Interest  
Grand Ballroom A/B, Main Level

Program  
Co-Chairs: Mitchell Brin, MD, Allergan, Inc.; Kathleen Clarence-Smith, MD, PhD, KM Pharmaceutical Consulting LLC

7:00 p.m. – 7:10 p.m. Alan Faden, MD, Neurotherapeutics® Editor-in-Chief, Ten Volumes of Excellence  
Presentation made by Howard Federoff, MD to Alan Faden, MD

7:15 p.m. – 8:30 p.m. Conflict of Interest  
Speakers: Josephine Torrente, JD, Hyman, Phelps & McNamara; Sheila Walcoff, JD, Goldbug Strategies LLC
### Program Schedule (Continued)

**FRIDAY, FEBRUARY 21, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m. – 9:00 a.m.</td>
<td><strong>Cognition Workshop</strong></td>
</tr>
<tr>
<td>Grand Ballroom A/B, Main Level</td>
<td><strong>Program</strong>  Co-Chairs: Amy Chappell, MD; Jill Rasmussen, MD, Psi-Napse</td>
</tr>
<tr>
<td>7:30 a.m. – 7:40 a.m.</td>
<td>Introduction</td>
</tr>
<tr>
<td>7:40 a.m. – 8:10 a.m.</td>
<td><strong>Designing a Battery for Clinical Trials: The MATRICS Project for Schizophrenia</strong></td>
</tr>
<tr>
<td>8:10 a.m. – 8:40 a.m.</td>
<td><strong>The Problem of Cognitive Dysfunction/Decline in Epilepsy</strong></td>
</tr>
<tr>
<td>8:40 a.m. – 9:00 a.m.</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>9:15 a.m. – 12:30 p.m.</td>
<td><strong>Psychiatric Pharmacogenomics: From Single DNA Nucleotides to Improved Patient Care</strong></td>
</tr>
<tr>
<td>Grand Ballroom C, Main Level</td>
<td><strong>Program</strong>  Chair: C. Anthony Altar, PhD, AssureRx Health, Inc.</td>
</tr>
<tr>
<td>9:15 a.m. – 9:25 a.m.</td>
<td>Introduction</td>
</tr>
<tr>
<td>9:25 a.m. – 10:00 a.m.</td>
<td><strong>Gene Polymorphisms: How They Alter Enzymes, Transporters and CNS Response Proteins</strong></td>
</tr>
<tr>
<td>10:00 a.m. – 10:35 a.m.</td>
<td><strong>Challenges in Bringing Psychiatric Pharmacogenomics to the Clinic</strong></td>
</tr>
<tr>
<td>10:35 a.m. – 11:10 a.m.</td>
<td><strong>Using Combinatorial Pharmacogenomics to Predict and Improve Antidepressant Outcomes</strong></td>
</tr>
<tr>
<td>11:10 a.m. – 11:25 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>11:25 a.m. – 12:10 p.m.</td>
<td><strong>Next-Generation Sequencing Pharmacogenomics for Psychiatry and CNS Therapeutics</strong></td>
</tr>
<tr>
<td>12:10 p.m. – 12:30 p.m.</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>
### Special Interest Topics and Luncheon

**Time:** 12:45 p.m. – 2:00 p.m.

**Location:** White Oak, Lower Level

- Health Information Technology (HIT) as a Tool to Enable Comparative Effectiveness Research
- How Can Phase I Inform Efficacy?
- What are Appropriate Expectations for Animal Models?
- How to Most Efficiently Find the Right Dose
- How to use Social Media to Engage Patients in Clinical Research
- Innovation in Clinical Patient Data Collection: Use of Smart Phones and Other Remote Monitoring Techniques
- Challenges to Young Researchers Entering the Field of Neurotherapeutics
- Challenges to International Drug Development
- Drug Development and Health Care Reform
- How Much Safety Must We Have to Support Marketing Authorization and to Get to Phase III Trials?
- Challenges for Start-Up Companies to Achieve Proof of Concept

### Pipeline Session

**Time:** 2:15 p.m. – 6:00 p.m.

**Location:** Grand Ballroom A/B, Main Level

Chair: Philip Perera, MD, Dart Neuroscience LLC

Investigators in academia, government, industry and advocacy present an update on research and development progress on a specific project in the broad area of neurotherapeutics. Such projects may address neurological disorders, psychiatric disorders, pain, neuro-oncology, neurological infections or any other disorder affecting the central or peripheral nervous systems.
American Society for Experimental NeuroTherapeutics

Annual Business Meeting

Saturday, February 22, 2014
Bethesda North Marriott Hotel & Conference Center
Grand Ballroom A/B, Main Level
8:30 a.m. - 9:00 a.m.

Preliminary Agenda

I. Call to Order

II. Financial Report

III. Neurotherapeutics® Journal Report

IV. Membership Report

V. 17th Annual Meeting, February 2015

VI. Recognition of Outgoing Board Members

VII. Introduction of Incoming Board Members

VIII. Adjournment
### Program Schedule (Continued)

**SATURDAY, FEBRUARY 22, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m. – 9:00 a.m.</td>
<td><strong>ASENT Annual Business Meeting</strong></td>
<td>Grand Ballroom A/B, Main Level</td>
</tr>
</tbody>
</table>

### CONCURRENT SESSIONS:

**9:00 a.m. – 2:00 p.m.**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:10 a.m. – 11:45 a.m.</td>
<td><strong>Gene Therapy</strong></td>
<td>Grand Ballroom A/B, Main Level</td>
</tr>
</tbody>
</table>

**Program Chair:** Howard Federoff, MD, PhD, Georgetown University

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:10 a.m. – 9:20 a.m.</td>
<td><strong>Overview of CNS Gene Transfer as an Evolving Neurotherapeutic Modality</strong></td>
<td>Howard Federoff, MD, PhD, Georgetown University</td>
</tr>
<tr>
<td>9:20 a.m. – 9:35 a.m.</td>
<td><strong>FDA Regulatory Approach for Gene Therapy Clinical Trials</strong></td>
<td>Denise Gavin, PhD, FDA</td>
</tr>
<tr>
<td>9:35 a.m. – 9:55 a.m.</td>
<td><strong>AADC Gene Transfer for Movement Disorders</strong></td>
<td>Krystof Bankiewicz, MD, PhD, University of California, San Francisco</td>
</tr>
<tr>
<td>9:55 a.m. – 10:15 a.m.</td>
<td><strong>Prosavlin Gene Transfer to Parkinson’s Disease</strong></td>
<td>Stephane Palfi, MD, Henri Mondor Hospital</td>
</tr>
<tr>
<td>10:15 a.m. – 10:30 a.m.</td>
<td><strong>Using Functional Imaging to Measure Gene Transfer Function</strong></td>
<td>David Eidelberg, MD, Feinstein Institute for Medical Research</td>
</tr>
<tr>
<td>10:35 a.m. – 10:45 a.m.</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>10:45 a.m. – 11:45 a.m.</td>
<td><strong>Panel Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>11:45 a.m.</td>
<td><strong>Annual Meeting Adjourns</strong></td>
<td></td>
</tr>
</tbody>
</table>
# American Society for Experimental NeuroTherapeutics

## Program Schedule (Continued)

### SATURDAY, FEBRUARY 22, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m. – 2:00 p.m.</td>
<td><strong>Nuts, Bolts and Best Practices in the Conduct of Clinical Trials</strong></td>
</tr>
</tbody>
</table>

**Program**
Co-Chairs: Jesse Cedarbaum, MD, Consultant; Adam Butler, Bracket Global; Bernard Ravina, MD, Biogen Idec; Jeremy Shefner, MD, PhD, Upstate University Hospital

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
</table>
| 9:00 a.m. – 9:05 a.m. | Welcome and Introduction  
Session Co-Chairs |
| 9:05 a.m. – 9:25 a.m. | The Regulatory Framework for Drug Development  
Wilson Bryan, MD, FDA |
| 9:25 a.m. – 9:45 a.m. | Managing Clinical Trials in Your Practice: Site Management/Logistics  
Craig Curtis, MD, CPI, Compass Research |
| 9:45 a.m. – 10:05 a.m. | Managing Clinical Trials in Your Practice: Negotiation Prior to Start-Up  
Cornelia Kamp, MBA, University of Rochester |
| 10:05 a.m. – 10:25 a.m. | Managing Clinical Trials in Your Practice: Interfacing with the Operations Team  
Elizabeth Jones, RN, PAREXEL International |
| 10:25 a.m. – 10:45 a.m. | Managing Clinical Trials in Your Practice: Data  
Donna Hellsten, PPD |
| 10:45 a.m. – 11:05 a.m. | Managing Clinical Trials in Your Practice: Safety Reporting and SAE Management  
Mark Hosterman, INC Research |
| 11:05 a.m. – 11:25 a.m. | Managing Clinical Trials in Your Practice: What is an Audit and What to do if a Company or the FDA Audits You  
Elizabeth Troll, Quintiles |
| 11:25 a.m. – 11:55 a.m. | Break |
| 11:55 a.m. – 12:15 p.m. | The “Intangibles:” Patient Recruitment and Retention  
Karen Bell, MD, Columbia University |
| 12:15 p.m. – 12:35 p.m. | The “Intangibles:” What is “Informed” Consent?  
E. Ray Dorsey, MD, MBA, University of Rochester |
12:35 p.m. – 12:55 p.m. The “Intangibles:” Quality, Quality, Quality  
David Miller, MD, Bracket Global

12:55 p.m. – 1:15 p.m. The “Intangibles:” The Importance of Training  
Amy Veroff, Cogstate

1:15 p.m. – 1:30 p.m. The “Intangibles:” What Sponsors/Groups Look for from Industry  
O’Neill D’Cruz, MD, MBA, UCB, Inc.

1:30 p.m. – 1:45 p.m. The “Intangibles:” What Sponsors/Groups Look for from Academic Consortia  
James Caress, MD, Wake Forest University School of Medicine

1:45 p.m. – 2:00 p.m. Panel Discussion: Interpreting Clinical Trial Data and Discussing New Outcomes with Patients  
Jesse Cedarbaum, MD, Moderator

2:00 p.m. Adjourn
To obtain a CME certificate for the ASENT 16th Annual Meeting, please access the online evaluation on our website, www.asent.org. A link to the evaluation is on the homepage. Evaluations must be completed by Saturday, March 22, 2014, in order to receive credit.

ASENT’s 16th Annual Meeting has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Vermont and the American Society for Experimental NeuroTherapeutics. The University of Vermont is accredited by the ACCME to provide continuing medical education for physicians.

The University of Vermont designates this live activity for a maximum of 17 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Your number of credits will be determined based on the questions you answer in the online evaluation.
Session Objectives: At the completion of the meeting, participants will be able to:

• Create trial designs that comply with standardized clinical trials measures that are acceptable and approved by pharmaceutical companies, government agencies, FDA, investigators and patient populations and that would be coordinated to avoid confusion and subsequently allow learners to prepare new protocols without errors, redundancy or omissions, ultimately streamlining the review process; and

• Obtain updated information regarding gene polymorphisms, how they alter drug metabolism, protein degradation in various patient populations exposed to medications. Participant should be able to use pharmacogenomics responses to predict outcomes clinically utilizing psychiatric drugs as a basis for model design.

Meeting Disclaimer: Regarding written materials and information received, written or otherwise, during this activity: The scientific views, statements and recommendations expressed during this CME activity represent those of the authors, and speakers and do not necessarily represent the views of the University of Vermont.

Interest Disclosures: As an organization accredited by the ACCME to sponsor continuing medical education activities, The University of Vermont is required to disclose any real or apparent conflicts of interest (COI) that any speakers may have related to the content of their presentations.

The University of Vermont requires that each speaker participating in a program designated for AMA Physician’s Recognition Award Category 1 credit disclose any financial interest/arrangement or affiliation with a corporate organization that may impact on his/her presentation (i.e. grants, research support, honoraria, member of speakers’ bureau, consultant, major stock shareholder, etc.)

No Interests to Disclose:

Wilson Bryan, MD
Laurie Burke, RPh, MPH
James Caress, MD
Maria Carrillo, PhD
Jesse Cedarbaum, MD**
David Cella, PhD
Amy Chappell, MD**
E. Ray Dorsey, MD, MBA
David Eidelberg, MD
Robin Elliott, MA**
Andrea Gaedigk, PhD
Wendy Galpern, MD, PhD
Denise Gavin, PhD
Robert Hamill, MD**
Jill Heemskerk, PhD
Jack Judy, MD

Petra Kaufmann, MD, MSc
Kevin Keim, PhD, MSc
Douglas Kerr, MD, PhD
Victor Krauthamer, PhD
Bennett Lavenstein, MD**
Martha Morrell, MD**
Brian Pasley, PhD
Gabriel Silva, PhD
Glenn Stebbins, PhD
Diane Stephenson, PhD
Josephine Torrente, JD
Amy Veroff
Sheila Walcoff, JD
Marc Walton, MD, PhD**
Richard Weinshilboum, MD
Antony Zorzos, PhD
Interests to Disclose/COI/Bias Resolved*:

C. Anthony Alter, PhD**
AssureRx Health, Inc., employee

Krystoff Bankiewicz, MD, PhD
Voyager Therapeutics, financial interest; uniQuire, financial interest

Karen Bell, MD
Baxter, stock; Pfizer, research support

Mitchell Brin, MD**
Allergan, employee

Adam Butler**
Bracket Global LLC, employee; ExpressScripts Inc, shareholder

Kathleen Clarence-Smith, MD, PhD**
KM Pharmaceutical Consulting, employee; Chase Pharmaceuticals, chairman; Kurma Bofnd, consultant; Key Neuroscience, consultant

Shaun Comfort, MD**
Adaptix Clinical Solutions, LLC, employee; Incline Therapeutics, consultant; Cyberonics, consultant; Invictus Medical, consultant; Anthera Pb, consultant

O’Neill D’Cruz, MD, MBA
UCB Pharma, employee

Donna Hellsten, PPD
employee

Mark Hosterman, PharmD
INC Research, employee

Elizabeth Jones, RN
PAREXEL International, employee

Cornelia Kamp, MBA
Clintrex, LLC, consultant
Richard Keefe, PhD

Investigator-initiated research funding support from Dept. of Veteran’s Affairs, Feinstein Institute for Medical Research, GlaxoSmithKline, NIH/NIMH, Novartis, Psychogenics, Research Foundation for Mental Hygiene, and Singapore National Medical Research Council; received honoraria, served as a consultant, or advisory board member for Abbvie, Akebia, Amgen, Astellas, Asubio, AviNeuro/ChemRar, BiolineRx, Biomarin, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, EnVivo, Helicon, Lundbeck, Merck, Mitsubishi, Otsuka, Pfizer, Roche, Shire, Sunovion, Takeda, Targacept

Kimford Meador, MD

NIH/NINDS, research grants; UCB Pharma, research grants; Epilepsy Study Consortium, consultant

David Miller, MD

Bracket Global, employee; Express Scripts, stockholder

Martha Morrell, MD

NeuroPace, Inc., employee

Stephane Palfi, MD

Oxford Biomedia, honorarium

Philip Perera, MD

Dart NeuroScience, employee

Roy Perlis, MD, MSc

Genomind, consultant; PsyBrain, consultant; Proteus, consultant; Pamlab, consultant; Pfizer, consultant; RIDVentures, consultant

Roger Porter, MD

Lilly, consultant; NeuroPace, consultant; Upsher-Smith, consultant; Medivation, consultant; Civitas, consultant; Astellos, consultant; SK Pharma, consultant

Jill Rasmussen, MD

Psi-Napse, director

Bernard Ravina, MD, MS

Biogen Idec, employee and stock holder

Nancy Santilli, MSN

Endo Health Solutions, employee
Jeremy Shefner, MD, PhD
Cytokinetics, consultant; ISIS, consultant; Synaerion, consultant

William Theodore, MD**
Common stock ownership in IBM, CSCO, XOM, PG, SJM, HON

*Having a financial interest or other relationship with a corporate organization may not prevent a speaker from making a presentation; however, the existence of the relationship must be made known to the planning committee prior to the conference so that any possible conflict of interest may be resolved prior to the talk.

**ASENT Program Committee
American Society for Experimental NeuroTherapeutics

16th Annual Meeting
Program Committee

Bennett Lavenstein, MD, Co-Chair
Children’s Hospital Medical Center

Martha Morrell, MD, Co-Chair
NeuroPace, Inc.

C. Anthony, Altar, PhD
AssureRx Health, Inc.

Mitchell Brin, MD
Allergan, Inc.

Jesse Cedarbaum, MD
Consultant

Amy Chappell, MD

Kathleen Clarence-Smith, MD, PhD
KM Pharmaceutical Consulting, LLC

Shaun Comfort, MD, MBA
Adaptix Clinical Solutions, LLC

Robin Elliott, MA
Parkinson’s Disease Foundation

Robert Hamill, MD
University of Vermont

Philip Perera, MD
Dart Neuroscience LLC

Roger Porter, MD

Jill Rasmussen, MD
Psi-Napse

William H. Theodore, MD
National Institutes of Health
American Society for Experimental NeuroTherapeutics

ASENT 2013 - 2014
Board of Directors

PRESIDENT
Michael Rogawski, MD, PhD
University of California, Davis

PRESIDENT-ELECT
Howard Federoff, MD, PhD
Georgetown University

IMMEDIATE PAST PRESIDENT
Robert W. Hamill, MD
University of Vermont

SECRETARY
Jesse Cedarbaum, MD
Consultant

TREASURER
Robin Elliott, MA
Parkinson’s Disease Foundation

DIRECTORS 2011-2014
Rohit Bakshi, MD, FAAN
Brigham and Women’s Hospital

Russell Katz, MD

Jill Rasmussen, MD
Psi-Napse

Richard Rudick, MD
Cleveland Clinic

DIRECTORS 2012-2015
Steven DeKosky, MD
University of Virginia School of Medicine

Robert Griggs, MD
University of Rochester

Philip Perera, MD, MBA
Dart NeuroScience LLC

DIRECTORS 2013-2016
Timothy Coetzee, Ph.D.
National Multiple Sclerosis Society

Joseph Hulihan, M.D.
Janssen Global Services

Lynn Kramer, M.D.
Eisai, Inc.

Bernard Ravina, M.D.
Biogen Idec, Inc.

EX-OFFICIO
DEVELOPMENT COMMITTEE CHAIR
Kathleen Clarence-Smith, MD, PhD
KM Pharmaceutical Consulting, LLC

NEUROTHERAPEUTICS® EDITOR-IN-CHIEF
Alan Faden, MD
University of Maryland School of Medicine

PROGRAM COMMITTEE CO-CHAIRS
Bennett Lavenstein, MD
Children’s Hospital Medical Center

Martha Morrell, MD
NeuroPace, Inc.

NIH BLUEPRINT COURSE LIAISON
Barbara Slusher, PhD, MBA
Johns Hopkins School of Medicine

FEDERAL LIAISON
Rajesh Ranganathan, PhD
NIH/NINDS

EXECUTIVE DIRECTOR
Charles H. Marsh, CAE, IOM
Future Meetings

ASENT 17th Annual Meeting
February 19 – 21, 2015
Georgetown University Hotel & Conference Center
Washington, D.C.

Abstract submissions begin
June 2, 2014

ASENT/ISCTM
Joint Educational Session
February 19, 2015
Fairmont Hotel
Washington, D.C.
Wednesday, February 19, 2014
5:30 p.m. – 8:00 p.m. Registration
Foyer, Grand Ballroom C, Main Level
6:00 p.m. – 8:00 p.m. Welcome Reception
Grand Ballroom C, Main Level

Thursday, February 20, 2014
7:30 a.m. – 6:00 p.m. Registration
Foyer, Grand Ballroom C, Main Level
8:00 a.m. – 12:00 p.m. Commonalities in the Development of Clinical Trial Measures in Neurology
Grand Ballroom A/B, Main Level
12:00 p.m. – 1:15 p.m. Clinical Trial Measures Working Groups Luncheon
White Oak, Lower Level
1:15 p.m. – 1:45 p.m. Clinical Trial Measures Reports and Wrap-Up
White Oak, Lower Level
3:30 p.m. - 5:00 p.m. Animal Research and Brain Diseases
Linden Oak, Lower Level
5:00 p.m. – 6:30 p.m. Information Exchange and Poster Presentation Reception
Grand Ballroom C, Main Level
6:30 p.m. – 8:30 p.m. Dinner Session – Conflict of Interest

Friday, February 21, 2014
7:30 a.m. – 6:00 p.m. Registration
Foyer, Grand Ballroom C, Main Level
7:30 a.m. – 9:00 a.m. Cognition Workshop
Grand Ballroom A/B, Main Level
9:15 a.m. – 12:30 p.m. Psychiatric Pharmacogenomics: From Single DNA Nucleotides to Improved Patient Care
Grand Ballroom A/B, Main Level
12:45 p.m. – 2:00 p.m. Special Interest Topics and Luncheon
White Oak, Lower Level
2:15 p.m. – 6:00 p.m. Pipeline Session
Grand Ballroom A/B, Main Level

Saturday, February 22, 2014
8:00 a.m. – 12:00 p.m. Registration
Foyer, Grand Ballroom C, Main Level
8:30 a.m. – 9:00 a.m. Annual Business Meeting
All members are welcome!
Grand Ballroom A/B, Main Level
9:00 a.m. – 2:00 p.m. Nuts, Bolts and Best Practices in the Conduct of Clinical Trials
Grand Ballroom C, Main Level
9:10 a.m. – 11:45 a.m. Gene Therapy
Grand Ballroom A/B, Main Level